The efficacy of deferoxamine in preventing nephrotoxicity of anthracyclins in pediatric cancer patients
Phase 3
- Conditions
- ephropathy of Anthracyclins.Nephropathy induced by other drugs, medicaments and biological substances
- Registration Number
- IRCT2016021915666N3
- Lead Sponsor
- Vice chancellor of research, Shiaz Univeisity of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
signing informed consent; male or female aged between 2-18 years at screening; new pediatric cancer patients who are going to receive Anthracyclin drugs as part of their chemotherapy regimen. Exclusion criteria: patients below two years old; patients with previous history of treatment with any kind of chemotherapy or radiotherapy; diagnosis of primary or metastatic renal tumors; patients with congenital or acquired renal problems
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood Urea Nitrogen. Timepoint: before and after chemotherapy coarse. Method of measurement: Photometric.;Serum creatinin. Timepoint: before and after chemotherapy coarse. Method of measurement: Photometric.;Urine N-acetyl beta glucoseaminidase. Timepoint: before and after chemotherapy coarse. Method of measurement: N-acetyl-beta-glucosaminidase assay.;Urine creatinin. Timepoint: before and after chemotherapy coarse. Method of measurement: Collection of 24 hours urine.;Urine protein. Timepoint: before and after chemotherapy coarse. Method of measurement: Collection of 24 hours urine.;Micro-albuminuria (Urine albumin-to-creatinine ratio). Timepoint: before and after chemotherapy coarse. Method of measurement: Immuno-turbidimetric.;Nephropathy sign. Timepoint: before and after chemotherapy coarse. Method of measurement: Sonograghy.
- Secondary Outcome Measures
Name Time Method